Could a New Gene Therapy Revolutionize Lung Treatment via Nasal Spray?
Click to start listening
Synopsis
A groundbreaking gene therapy developed by US researchers could change the way respiratory diseases are treated. With a nasal spray method, this therapy potentially targets the lungs more effectively than ever before. Discover how this innovative technology could revolutionize treatment options for conditions like pulmonary fibrosis and COVID-19.
Key Takeaways
- AAV.CPP.16 is a new gene therapy variant for lung treatment.
- The therapy is delivered via a nasal spray.
- It has shown superior performance compared to older versions.
- Potential applications include treating pulmonary fibrosis and COVID-19.
- Further research is essential to confirm its efficacy.
New Delhi, May 23 (NationPress) - Researchers in the United States have developed an innovative gene therapy designed to target the airway and lungs through a nasal spray.
For gene therapy to be effective, it is crucial that therapeutic molecules are delivered accurately to their intended sites within the body. This is typically achieved using adeno-associated viruses (AAV) for gene therapy.
To enhance the AAV's capability to deliver treatments specifically to the lungs and airways, scientists at Mass General Brigham have engineered a new variant named AAV.CPP.16, which is suitable for administration via nasal spray.
In preclinical trials, AAV.CPP.16 surpassed earlier versions by significantly improving targeting to the airway and lungs, demonstrating potential for respiratory and lung gene therapy, as noted by the researchers in their study published in the journal Cell Reports Medicine.
“We observed that AAV.CPP.16, originally designed to penetrate the central nervous system, also effectively targeted lung cells,” stated senior author FengFeng Bei from the Department of Neurosurgery at Brigham and Women's Hospital.
“This discovery led us to explore AAV.CPP.16 further for intranasal gene delivery to the respiratory airways,” added Bei.
In their research, AAV.CPP.16 demonstrated superior performance compared to previous versions (AAV6 and AAV9) in cell cultures, mouse models, and non-human primate studies.
“Our results underscore AAV.CPP.16 as a promising vector for respiratory and lung gene therapy,” the team remarked.
They subsequently employed this more effective tool to administer gene therapy aimed at preventing scarring in cases of pulmonary fibrosis, utilizing a mouse model of the respiratory ailment.
Additionally, they utilized the tool to deliver gene therapy for a viral infection, successfully inhibiting the replication of the SARS-CoV-2 virus in a mouse model of COVID-19.
“While additional research is necessary, our findings indicate that intranasal AAV.CPP.16 possesses significant translational potential as a reliable delivery mechanism for targeting the airway and lungs,” concluded Bei.
Point of View
I observe the transformative potential of advancements in medical science. This new gene therapy, utilizing a nasal spray for targeted lung treatment, demonstrates the innovative spirit of researchers dedicated to improving health outcomes. It is essential that we continue to support and monitor such pioneering work, as it holds the promise of significant benefits for patients with respiratory conditions.
NationPress
08/06/2025
Frequently Asked Questions
What is AAV.CPP.16?
AAV.CPP.16 is a newly engineered variant of adeno-associated virus designed to enhance the delivery of gene therapies specifically to the lungs and airways.
How does the therapy work?
The therapy utilizes a nasal spray to deliver therapeutic molecules directly to the lung cells, improving targeting and effectiveness.
What diseases could this therapy potentially treat?
This therapy has shown promise in treating respiratory conditions such as pulmonary fibrosis and could potentially target infections like COVID-19.
What were the findings from the research?
The research indicated that AAV.CPP.16 outperformed earlier versions in targeting lung cells and has strong potential for future respiratory therapies.
Is further research needed?
Yes, while the findings are promising, additional research is necessary to fully understand the therapy's capabilities and its application in clinical settings.
